Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
OGN Stock Chart & Stats
$7.51
-$0.16(-1.02%)
At close: 4:00 PM EST
$7.51
-$0.16(-1.02%)
Day’s Range― - ―
52-Week Range$6.18 - $17.23
Previous CloseN/A
Volume728.75K
Average Volume (3M)7.66M
Market Cap
$1.84B
Enterprise Value$10.94B
Total Cash (Recent Filing)$672.00M
Total Debt (Recent Filing)$8.83B
Price to Earnings (P/E)3.7
Beta0.48
Next Earnings
Feb 12, 2026EPS Estimate
0.76Last Dividend Ex-Date
Nov 20, 2025Dividend Yield4.53%
Share Statistics
EPS (TTM)1.01
Shares Outstanding259,982,900
10 Day Avg. Volume6,479,037
30 Day Avg. Volume7,659,926
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)8.13
Price to Sales (P/S)0.60
P/FCF Ratio6.52
Enterprise Value/Market Cap5.96
Enterprise Value/Revenue1.74
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda6.95
Forecast
1Y Price Target
$8.75Price Target Upside16.51% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)3.82
Revenue Forecast (FY)$6.25B
Bulls Say, Bears Say
Bulls Say
Cash FlowOGN expects more than $900mn in free cash flow before one-time costs in 2025 and expects one-time costs to decline in 2026.
DivestitureOGN divested its JADA System for $440mn with additional milestone payments up to $25mn.
Financial GoalsThe company continues to target net debt to adjusted EBITDA ratio of less than 4x.
Bears Say
Financial ControlsThe company's Board determined that certain prior statements were inaccurate or incomplete, prompting remedial steps to strengthen financial controls.
Leadership ChangesThe resignation of CEO Kevin Ali was announced following an investigation into improper purchasing practices related to Nexplanon.
Revenue GuidanceOGN lowered revenue guidance to $6.20bn-$6.25bn predominantly driven by US policy headwinds for Nexplanon and challenges in the respiratory business.
Organon News
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $6.18 and its highest was $17.23 in the past 12 months.
What is Organon’s market cap?
Organon’s market cap is $1.84B.
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Feb 12, 2026 which is in 77 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Nov 10, 2025. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.936 by $0.074.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.02 which represents an annual dividend yield of 4.53%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is 0.76.
How many shares outstanding does Organon have?
Organon has 259,982,900 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.01 in its last earnings report, beating expectations of $0.936. Following the earnings report the stock price went up 13.757%.
Which hedge fund is a major shareholder of Organon?
Currently, no hedge funds are holding shares in OGN
Organon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$8.75 (16.51% Upside)
$8.75 (16.51% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 190.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $501.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.60%
12-Months-Change
Fundamentals
Return on Equity
71.62%
Trailing 12-Months
Asset Growth
6.27%
Trailing 12-Months
Company Description
Organon
Organon (OGN) is a global healthcare company focused on women's health and other critical health issues. Established as a standalone entity from Merck & Co., Organon specializes in developing and delivering innovative medicines and solutions that address the unique health needs of women throughout their life stages. The company offers a diverse portfolio of products, including contraceptives, hormone replacement therapies, and treatments for conditions such as infertility, endometriosis, and osteoporosis.
OGN Company Deck
OGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong operational metrics like adjusted EBITDA margin and free cash flow, alongside significant challenges in key segments like Nexplanon and respiratory, leading to a downward revenue guidance revision. The divestiture of Jada offers potential for financial improvement, but the impact of past sales practices remains a concern.View all OGN earnings summariesOGN Stock 12 Month Forecast
Average Price Target
$8.75
▲(16.51% Upside)
Technical Analysis
Ownership Overview
0.33% Insiders
21.38% Mutual Funds
8.31% Other Institutional Investors
46.11% Public Companies and Individual Investors